Adenosine 5′-monophosphate-activated protein kinase (AMPK) is a pivotal regulator of metabolism at cellular and organismal levels. AMPK also suppresses inflammation. We found that pharmacological activation of AMPK rapidly inhibited the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway in various cells. In vitro kinase assays revealed that AMPK directly phosphorylated two residues (Ser 515 and Ser 518 ) within the Src homology 2 domain of JAK1. Activation of AMPK enhanced the interaction between JAK1 and 14-3-3 proteins in cultured vascular endothelial cells and fibroblasts, an effect that required the presence of Ser 515 and Ser 518 and was abolished in cells lacking AMPK catalytic subunits. Mutation of Ser 515 and Ser 518 abolished AMPK-mediated inhibition of JAK-STAT signaling stimulated by either the sIL-6Ra/IL-6 complex or the expression of a constitutively active V658F-mutant JAK1 in human fibrosarcoma cells. Clinically used AMPK activators metformin and salicylate enhanced the inhibitory phosphorylation of endogenous JAK1 and inhibited STAT3 phosphorylation in primary vascular endothelial cells. Therefore, our findings reveal a mechanism by which JAK1 function and inflammatory signaling may be suppressed in response to metabolic stress and provide a mechanistic rationale for the investigation of AMPK activators in a range of diseases associated with enhanced activation of the JAK-STAT pathway.
INTRODUCTION
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway mediates signaling by a range of cytokines that can stimulate or inhibit survival, proliferation, and differentiation responses in diverse cell types. JAKs comprise a family of four cytoplasmic tyrosine kinases (JAK1, JAK2, JAK3, and Tyk2) that function as essential signaling components immediately downstream of receptors for many hematopoietic cytokines, such as granulocyte-macrophage colony-stimulating factor, erythropoietin, leptin, interferons (IFNs), and interleukins such as interleukin-6 (IL-6) (1, 2). The IL-6 receptor comprises two distinct subunits, an IL-6-binding protein [interleukin-6 receptor a (IL-6Ra)] and a 130-kDa signal-transducing subunit [glycoprotein 130 (gp130)], which is shared by all cytokines of the IL-6 family (2). The gene encoding gp130 is ubiquitously expressed, whereas that encoding IL-6Ra is restricted to hepatocytes, monocytes, neutrophils, and some B and T cell subsets. However, IL-6 can also bind a soluble form of the receptor [soluble IL-6Ra (sIL-6Ra)] generated by either limited proteolytic cleavage of membrane-bound IL6Ra or alternate splicing of IL-6Ra primary transcripts. The resulting sIL-6Ra/IL-6 "trans-signaling" complexes can then associate with gp130 in cells that do not express the membrane-bound IL-6R, thereby widening the spectrum of IL-6-responsive cells (3) .
IL-6 binding to the receptor complex results in the activation of gp130-bound JAKs. The activated JAKs can then phosphorylate specific Tyr residues within the receptor's cytoplasmic domain, which serve as docking sites for Src homology 2 (SH2) domain-containing proteins. The major intracellular mediators are the STAT proteins. IL-6 is capable of activating STAT1 and STAT3, although STAT3 activation has been observed to a greater extent than STAT1. Activation of STATs requires their recruitment to specific JAK-phosphorylated Tyr residues on gp130 via their SH2 domain, followed by JAK-mediated phosphorylation of a Tyr residue in the transactivation domain (Tyr 705 on STAT3 and Tyr 701 on STAT1). Tyr-phosphorylated STATs then form dimers that can translocate to the nucleus to activate target gene transcription. IL-6 can also activate extracellular signal-regulated kinase 1 (ERK1) and ERK2 and phosphatidylinositol 3-kinase (PI3K) pathways after recruitment of SH2-containing protein tyrosine phosphatase 2 (SHP2) to JAK-phosphorylated gp130 (2, 4) .
Adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) is the highly conserved downstream component of a Ser/Thr protein kinase cascade involved in the regulation of metabolism. It was initially characterized as a Ser/Thr protein kinase that is allosterically activated by increases in intracellular AMP concentration, resulting from a decline in intracellular adenosine 5′-triphosphate (ATP) that occurs after nutrient deprivation or hypoxia (5, 6) . AMPK is a heterotrimeric complex consisting of a catalytic a subunit and regulatory b and g subunits. In mammals, isoforms of each subunit (a1, a2, b1, b2, g1, g2, and g3) are encoded by seven genes. The b subunits are each N-terminally myristoylated, contain carbohydrate-binding domains, and interact with both the a and g subunits, whereas the g subunits contain the AMP/ADP (adenosine 5′-diphosphate) binding sites responsible for sensing cellular energy status [reviewed in (5) ]. In addition to the allosteric activation of AMPK by adenine nucleotides, AMP or ADP binding to the regulatory g subunit of AMPK promotes phosphorylation of the catalytic a subunit at Thr 172 , which is required for AMPK activity. Binding of AMP and ADP also inhibits dephosphorylation of AMPK, maintaining Thr 172 phosphorylation by the upstream AMPK Thr 172 kinase liver kinase B1 (LKB1) (5, 6) . In the absence of changes in adenine nucleotide ratios, AMPK can be activated by increases in intracellular Ca 2+ concentrations in cells expressing Ca 2+ /calmodulin-dependent protein kinase kinase b (CaMKKb) (5, 6) .
The most studied aspect of AMPK function is its role in maintaining cellular energy stores and regulating whole-body energy balance. An important aspect of this role is the direct phosphorylation of metabolic enzymes, such as acetyl-coenzyme A (CoA) carboxylase 1 (ACC1) and ACC2, which catalyze the carboxylation of acetylCoA to malonyl-CoA, a key substrate for fatty acid biosynthesis that also inhibits fatty acid transport into the mitochondria (7). AMPKmediated phosphorylation of ACC1 on Ser 79 inhibits its activity, thereby suppressing fatty acid synthesis and enhancing b-oxidation (8) . An increasing body of evidence has revealed that AMPK is also an important regulator of inflammatory responses. For example, AMPK-dependent inhibition of tumor necrosis factor-a (TNFa)-, lipopolysaccharide (LPS)-, and IL-1b-stimulated leukocyte recruitment to vascular endothelial cells (ECs) in culture has been observed in multiple studies and is associated with reduced induction of adhesion molecules [such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin] and chemokines (such as CCL2 and CCL3) (9, 10).
Studies using PRKAA1
−/− and PRKAA2 −/− mice, which lack AMPKa1 and AMPKa2 catalytic subunits, respectively, suggest that both isoforms can contribute to the inhibition of postischemic leukocyte adhesion to blood vessels by the AMPK activator 5′-aminoimidazole-4-carboxamide ribonucleoside (AICAR) (11) . Consistent with a role for AMPK in suppressing inflammation in vivo, aortae from AMPKa1 −/− mice have been shown to display enhanced angiotensin II-stimulated VCAM-1 expression (12) . Activation of AMPK with AICAR is also associated with reduced infiltration of inflammatory cells in rodent models of acute and chronic colitis (13) , lung injury (14) , and autoimmune encephalomyelitis (15) . Furthermore, increased infiltration and activation of macrophages have been observed in adipose tissue from wild-type mice transplanted with bone marrow from AMPKb1 −/− mice (16) . Therefore, taken as a whole, it has become clear that AMPK can limit inflammatory cell infiltration and activation in multiple settings.
Although the ability of AMPK to maintain fatty acid oxidation in macrophages has been proposed as an important mechanism by which it limits inflammation in macrophages (16) , several mechanisms have also been identified through which AMPK can directly inhibit pro-inflammatory signaling pathways. However, although several potential mechanisms have been proposed to explain AMPK-mediated inhibition of the nuclear factor kB pathway in response to stimuli such as TNFa, LPS, and IL-1 (9, 17) , relatively few studies have examined how the JAK-STAT pathway is controlled by AMPK. This is a particularly important issue to address, given the pathological roles of enhanced JAK-STAT signaling in multiple chronic inflammatory conditions, such as atherosclerosis, colitis, and rheumatoid arthritis, as well as several cancers and hematological disorders driven by mutational activation of JAK isoforms (1, (18) (19) (20) .
Here, we found that AMPK could rapidly and profoundly inhibit activation of the JAK-STAT pathway in response to multiple stimuli. In addition, we show that this occurs through a previously unappreciated mechanism involving direct AMPK-mediated phosphorylation of JAK1 within its regulatory SH2 domain. Therefore, our data reveal how metabolic stress can rapidly inhibit signaling from JAK1 and provide a molecular basis for potential repurposing of AMPK activators for a range of diseases associated with enhanced activation of the JAK-STAT pathway.
RESULTS
AMPK rapidly inhibits IL-6 signaling and function AMPK plays a largely protective role in vascular ECs via both nitric oxide (NO)-dependent and NO-independent mechanisms (21, 22) . Incubation of human umbilical vein ECs (HUVECs) with sIL-6Ra/ IL-6 trans-signaling complexes for 30 min significantly increased the phosphorylation of STAT3 on Tyr 705 (Fig. 1A) , an effect that was significantly inhibited in HUVECs that had been preincubated with distinct stimuli that each activate AMPK, as determined by assessing ACC1 phosphorylation on Ser 79 (8) : AICAR, which is phosphorylated intracellularly to the AMP mimetic ZMP (23); A769662, which binds and activates b1-containing AMPK complexes via an AMP/ADPindependent mechanism (24); and a combination of clinically used AMPK activators metformin and salicylate, which synergistically activate AMPK by increasing intracellular AMP concentration and directly binding b1 subunits, respectively (25) (26) (27) . Under these conditions, AMPK activation on its own had no detectable effect on the phosphorylation of STAT3. Targeted short inhibitory RNA (siRNA)-mediated knockdown of AMPKa1 catalytic subunits reduced the inhibitory effects of both A769662 (Fig. 1B) and AICAR ( fig. S1 ), indicating that these effects were mediated via AMPK activation. In addition, compared with controls, adenovirus (AV)-mediated expression of a catalytically inactive dominant-negative (DN) AMPKa1 subunit, in which Asp 157 located within subdomain VII of the catalytic domain is mutated to Ala (28) , was sufficient to block A769662-mediated inhibition of STAT3 phosphorylation in HUVECs ( fig. S1 ). Together, these data demonstrated that activation of AMPK by multiple stimuli triggered a rapid and significant reduction in the ability of sIL-6Ra/ IL-6 to stimulate STAT3 phosphorylation on Tyr 705 . To assess the functional consequences of AMPK-mediated inhibition of IL-6 signaling, we initially examined the effect of A769662 on IL-6-mediated induction of STAT3 target genes suppressor of cytokine signaling 3 (SOCS3) and CCAAT/enhancer binding protein d (C/EBPd) (29, 30) . Similar to the effect on STAT3 phosphorylation, A769662 significantly inhibited sIL-6Ra/IL-6-stimulated accumulation of SOCS3 and C/EBPd protein (Fig. 1C) and mRNA (fig. S2) abundance. In addition, we took advantage of the well-described ability of IL-6 to induce chemokine expression and thereby increase monocyte chemotaxis (20, 31, 32) . Conditioned medium was collected from HUVECs cultured with vehicle, A769662, or sIL-6Ra/IL-6 and then applied to a Transwell migration assay to assess its capacity to stimulate monocyte migration. Because the HUVECs were extensively washed to remove A769662 and sIL-6Ra/IL-6 before collection of conditioned medium, it is unlikely that there was a substantial residual concentration of either that would directly contribute to migration. We found that the migration of U937 monocytic cells toward conditioned medium from sIL-6Ra/IL-6-stimulated HUVECs was significantly greater than that toward conditioned medium from vehicle-treated HUVECs (Fig. 1D) . Conditioned medium from HUVECs preincubated with A769662 for 30 min before cytokine stimulation elicited significantly less U937 cell migration compared to that from sIL-6Ra/IL-6-stimulated HUVECs (Fig. 1D) .
AMPK inhibits signaling from multiple cytokine receptor complexes To identify the point in the IL-6 signaling pathway at which AMPK was acting, we examined signaling downstream of multiple cytokines and other cytokine receptors. We found that the inhibitory effect of AMPK on sIL-6Ra/IL-6 responses was not restricted to STAT3, given that preincubation of HUVECs with A769662 also abrogated sIL-6Ra/ IL-6-stimulated phosphorylation of STAT1 on Tyr 701 ( Fig. 2A) . Whereas IL-6 signals downstream through interaction with either a membranebound or soluble IL-Ra and gp130 homodimers, leukemia inhibitory factor (LIF) and oncostatin M (OSM) signal through cytokine interaction with gp130/LIF receptor and gp130/ OSM receptor heterodimers, respectively (2). Similar to sIL-6Ra/IL-6, pretreatment of HUVECs with A769662 significantly reduced OSM-and LIF-stimulated phosphorylation of STAT3 and STAT1 ( Fig.  2A) . In addition, the ability of each cytokine to stimulate STAT3 phosphorylation on Ser
727
, which is critical for full transcriptional activation and is mediated by cytokine receptor activation of either the ERK1/2 or PI3K-mammalian target of rapamycin (mTOR) pathway, was similarly reduced by A769662 ( Fig. 2A) . In support of a postreceptor effect of AMPK, A769662 also suppressed STAT3 phosphorylation in response to IFNa, which activates STATs through a distinct IFNa/b receptor 1 (IFNAR1)/IFNAR2 complex that lacks gp130 ( Fig. 2B ) (33) . Together, these results would suggest that AMPK exerts its inhibitory effects on multiple cytokine-activated signaling pathways at one or more common loci downstream of both IFNAR1/IFNAR2 and gp130-containing cytokine receptor complexes.
JAK1 is phosphorylated by AMPK in vitro
The IFNAR1/IFNAR2 complex couples to STATs via JAK1 and Tyk2 (33, 34) . We performed JAK1, JAK2, and Tyk2 siRNA knockdown experiments in HUVECs, which demonstrated that JAK1 mediates a substantial proportion of sIL-6Ra/ IL-6-stimulated STAT3 activation (fig. S3). Thus, JAK1 was identified as a potential common AMPK-regulated postreceptor target. Because AMPK is a Ser/Thr protein kinase, and the inhibitory effect of AMPK activator A769662 occurred rapidly, we investigated the possibility that AMPK could directly phosphorylate JAK1. Peptide arrays of overlapping 25-mer peptides sequentially shifted by five amino acids and spanning the full human JAK1 open reading frame (residues 1 to 1154) were used for in vitro kinase assays with AMPK purified from rat liver and [g 32 P]ATP (35, 36) . These experiments identified a sequence within the JAK1 SH2 domain (R 506 YSLHGSDRSFPSLGDLMSHLKKQI) as a potential substrate whose phosphorylation on the array was greater than that of the so-called "SAMS" peptide, which is typically used as an in vitro substrate for assaying AMPK activity and is based on the primary AMPK phosphorylation site (Ser 79 ) in rat ACC1 (Fig. 3A) (35) . To determine which of the five potential phosphoacceptor sites within the JAK1 peptide were phosphorylated in vitro by AMPK, we then performed kinase assays on additional arrays containing the wild-type peptide sequence and mutant peptides in which each Ser residue was Cells were then preincubated with vehicle or A769662 and then stimulated with sIL-6Ra/ IL-6 as in (A). Data were analyzed as in (A); n = 3 independent experiments. (C) Immunoblotting of HUVECs pretreated with vehicle or A769662 (100 mM, 40 min) and stimulated with sIL-6Ra (25 ng/ml)/IL-6 (5 ng/ml) for 5 hours. Densitometry of SOCS3 and C/EBPd was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH); n = 3 independent experiments. (D) Chemotaxis of U937 promonocytic cells cultured in conditioned medium from HUVECs that were pretreated with vehicle or A769662 (100 mM, 30 min) and then stimulated with sIL-6Ra (25 ng/ml)/IL-6 (5 ng/ml) for 2 hours, washed, and incubated in fresh medium for conditioning for a further 1 hour. Data are means ± SEM; n = 3 independent experiments. *P < 0.05 and **P < 0.01 using a one-way analysis of variance (ANOVA) with Bonferroni post hoc test.
replaced with a nonphosphorylatable Ala residue either individually or in combination (Fig. 3B) . Simultaneous replacement of all five Ser residues with Ala abolished AMPK-mediated phosphorylation of the peptide. Individual replacement of each Ser residue with Ala either did not alter or enhanced AMPK phosphorylation of the resulting peptides. However, simultaneous replacement of Ser 515 and Ser 518 with Ala abrogated peptide phosphorylation to the same extent as mutating all five Ser residues. In addition, a peptide in which Ser 508 , Ser
512
, and Ser 524 were all replaced with Ala was phosphorylated to the same extent as the wild-type JAK1 sequence (Fig. 3B) . Together, these observations identified Ser 515 and Ser 518 in human JAK1 as potential sites of phosphorylation by AMPK in vitro.
Peptide library screening, mutagenesis, and molecular modeling studies (37, 38) have all been used to identify optimal AMPK substrate motifs. Bioinformatic analysis of JAK1 orthologs revealed that phosphorylation sites equivalent to Ser 518 in human JAK1 are conserved in multiple species (Fig. 3C ). Residues at positions +3 and +4 downstream of the phosphoacceptor sites that are known to be critical for substrate recognition are also well conserved (Fig. 3C) . Ser 518 is located at the start of a specific a helix that is conserved among all JAK isoforms (Fig. 3D) (39-41 ). In contrast, Ser 515 is unique to human JAK1 and will be predicted to only form a weak consensus for AMPK substrate recognition if Ser 518 became negatively charged by phosphorylation (Fig. 3C) AMPK mediates the phosphorylation of JAK1 in intact cells A common mechanism for phosphorylationmediated regulation of target protein function is phosphorylation-dependent binding to members of the 14-3-3 family of proteins (43) . To assess whether phosphorylation of Ser 515 and Ser 518 could facilitate JAK1 interaction with 14-3-3 proteins in vitro, we performed overlay assays with horseradish peroxidase (HRP)-conjugated 14-3-3z (HRP-14-3-3z) and peptide arrays comprising 25-mer peptides from the identified JAK1 region, in which either Ser 515 or Ser 518 or both were phosphorylated (Fig. 4A) . These demonstrated that phospho-Ser 515 and phospho-Ser 518 peptides strongly interacted with HRP-14-3-3z in vitro, although no binding was detectable with either nonphosphorylated peptide or peptide in which both Ser 515 and Ser 518 were phosphorylated (Fig. 4A) . A phosphorylation-dependent interaction with 14-3-3 proteins has been reported for several AMPK substrates, including autophagy-related protein 9 (ATG9), Raptor, and Unc-51-like autophagy-activating kinase 1 (ULK1) (38, 44, 45) . We tested our ability to detect such an interaction using two approaches. First, we compared the ability of bacterially expressed and affinity-purified glutathione S-transferase (GST)/14-3-3 fusion proteins to capture AMPK-phosphorylated JAK1 in pull-down assays from soluble extracts prepared from intact cells. Initial experiments in JAK1-null U4C human fibrosarcoma cells stably expressing recombinant JAK1 (46, 47) demonstrated that distinct GST/14-3-3 isoforms Densitometry of phosphorylated protein was normalized to that of the respective total fraction. Data are means ± SEM; n = 4 independent experiments. **P < 0.01 and ***P < 0.001 using a one-way ANOVA with Bonferroni post hoc test.
(B) Immunoblotting of HUVECs preincubated with vehicle or A769662 (100 mM, 30 min) and then stimulated with vehicle, sIL-6Ra (25 ng/ml)/IL-6 (5 ng/ml) (30 min), or IFNa (1000 U/ml, 15 min). Data were analyzed as in (A); n = 3 independent experiments. ***P < 0.001 using a one-way ANOVA with Bonferroni post hoc test.
(14-3-3z and 14-3-3t) but not GST alone could specifically isolate JAK1 ( fig. S4 ). To assess the importance of Ser 515 and Ser 518 in mediating this interaction, we used a different approach, in which wild-type and S515A/ S518A (SSAA)-mutated human JAK1 were transiently expressed in U4C cells before JAK1 was immunoprecipitated and resulting blots were overlaid with HRP-14-3-3z. Consistent with the peptide array overlays, these experiments demonstrated that, although wild-type JAK1 could be specifically identified, the SSAA-mutated JAK1 could not despite equivalent abundances of JAK1 in the immunoprecipitates ( fig. S4) . Finally, to assess the role of AMPK activation on JAK1 phosphorylation in intact cells, we transiently expressed wild-type and SSAAmutated human JAK1 in U4C cells before treatment with A769662 and preparation of cell extracts for pull-down assays with GST/14-3-3z and immunoblotting for JAK1 (Fig. 4B) . These demonstrated that A769662 treatment increased 14-3-3z interaction with JAK1 but not SSAA-mutant JAK1 despite an apparently equivalent activation of AMPK and expression of wild-type and mutant JAK1 in transfected cells (Fig. 4B) .
To further examine the AMPK dependence of this effect, we performed GST/ 14-3-3z pull-downs in wild-type murine embryonic fibroblasts (MEFs) and MEFs with no detectable AMPK activity because of homozygous deletion of AMPKa1 and AMPKa2 catalytic subunits (48) . AMPK activation with A769662 in wild-type MEFs transiently increased interaction of endogenous JAK1 with GST/14-3-3z, but this effect was absent in cells devoid of AMPK activity, as determined by the loss of ACC phosphorylation on Ser 79 (Fig.  4C) . Because murine JAK1 lacks Ser 515 or an equivalent residue (Fig. 3C) , this suggests that phosphorylation of Ser 517 alone on murine JAK1 is required for interaction with GST/14-3-3z. Finally, we examined the effects of combined metformin and salicylate treatment on AMPK-mediated JAK1 phosphorylation (as determined by interaction with GST/14-3-3z) in HUVECs, a condition in which we had found significantly inhibited sIL-6Ra/IL-6-stimulated STAT3 phosphorylation (Fig. 1A) . Combined treatment of HUVECs with metformin and salicylate significantly increased ACC phosphorylation and triggered a transient increase in the amount of endogenous JAK1 that was captured by GST/14-3-3z, which peaked about 1 hour after stimulation (Fig. 4D) .
AMPK-mediated inhibition of JAK1-dependent signaling requires Ser 515 and Ser 518
To investigate any contribution of AMPKmediated JAK1 phosphorylation on Ser 515 and Ser 518 toward regulating signaling, we used JAK1-null U4C human fibrosarcoma cells. Consistent with previous work (46) and our own siRNA experiments in HUVECs, loss of JAK1 was associated with no detectable sIL-Ra/IL-6-mediated phosphorylation of STAT3. However, transient expression of wild-type human JAK1 restored sIL-Ra/IL-6-mediated STAT3 phosphorylation over green fluorescent protein (GFP)-expressing controls, and this was inhibited by pretreatment with A769662 similar to the phenomenon observed in HUVECs (Fig. 5A) . Expression of SSAA-mutant JAK1 in U4C cells could also restore sILRa/IL-6-mediated STAT3 phosphorylation, but the ability of A769662 to inhibit this effect was lost despite maintaining its ability to activate AMPK as measured by ACC phosphorylation (Fig. 5B) . ) indicates that this sequence would potentially conform to a weak AMPK consensus site after the acquisition of negative charge upon its phosphorylation. (D) Alignment of SH2 domains from the four human JAK isoforms using T-Coffee modified to match the structural data available for JAK1, JAK2, and Tyk2 (39) (40) (41) . For clarity, only the alignment of the indicated regions within each SH2 domain is shown. The lettering above the alignment indicates secondary structural elements; the bG1 and bG2 regions present in the JAK2 and Tyk2 SH2 domains are moderately disordered in the only available JAK1 SH2 domain structure (39) . The residues corresponding to Ser 515 and Ser 518 in JAK1 are underlined and set in boldface, and the conserved Ser residues in JAK2, JAK3, and Tyk2 equivalent to We then examined the effects of AMPK activation on signaling downstream of a constitutively active V658F-mutant version of JAK1 found in patients with acute lymphoblastic leukemia (ALL) (49) . Analogous to the V617F mutation in JAK2, which is implicated in the etiology of several myeloproliferative neoplasms, this mutation within the JAK1 JH2 pseudokinase domain is thought to relieve an autoinhibitory interaction with the catalytic JH1 domain, thereby increasing Tyr kinase activity independent of cytokine stimulation (1, 50) . In contrast to wild-type JAK1, transient expression of V658F-mutant JAK1 in JAK1-null U4C cells was sufficient to trigger detectable Tyr phosphorylation of both STAT1 and STAT3 in the absence of added cytokine (Fig. 5C ). Exposing cells to A769662 increased ACC phosphorylation and inhibited STAT1 and STAT3 Tyr phosphorylation. Expression of V658F-mutant JAK1 incorporating the SSAA mutations also resulted in increased basal STAT phosphorylation, although this effect was less than that caused by V658F-mutant JAK1 expression.
However, A769662 treatment failed to significantly inhibit Tyr phosphorylation of STAT1 and STAT3 despite increasing ACC phosphorylation (Fig. 5C) . Together, these observations suggest that Ser 515 and Ser 518 in JAK1 are required for effective AMPK-mediated inhibition of JAK1-mediated downstream signaling to STAT1 and STAT3.
DISCUSSION
It is becoming increasingly apparent that cells can couple inflammatory status to the availability of nutrients (51, 52) . Conversely, the mechanisms by which nutrient availability can regulate inflammation remain unclear. Here, we demonstrate that direct phosphorylation of JAK1, a key signaling intermediate used by a variety of cytokines, can occur in response to stimulation of AMPK, a key determinant of cellular energy status, by multiple activators. In conjunction with other observations, this would suggest that energy stress triggers an LKB1-dependent activation of AMPK that can inhibit the JAK-STAT pathway through several distinct mechanisms. For example, others have shown that chronic AMPK activation in hepatocytes with metformin for 12 hours can increase levels of the orphan nuclear receptor "small heterodimer partner," which reduces STAT3 phosphorylation on Tyr 705 and colocalizes with nuclear STAT3 to reduce its binding to target gene promoters (53, 54) . Similarly, others have demonstrated that chronic treatment of hepatocytes with AICAR suppresses IL-6 signaling and is thought to involve an AMPK-mediated inhibition of IL-6-stimulated Tyr phosphorylation and activation of JAK1 and JAK2 and that depletion of AMPKa1 and AMPKa2 subunits could block the inhibitory effects of AMPK activators on cytokine-stimulated signaling without significantly altering basal activation (55, 56) . However, the underlying mechanisms were not investigated. Finally, AMPKmediated induction of mitogen-activated protein kinase phosphatase-1 (MKP-1) has been reported to play a critical role in suppressing STAT1 activation in aortic smooth muscle cells (57) . In contrast, we have demonstrated that AMPK-mediated phosphorylation of JAK1 within its regulatory SH2 domain is a rapid event mediated by direct AMPK activators (A769662 and salicylate) and mitochondrial inhibitors (metformin) and is required for AMPK to inhibit STAT3 activation by IL-6 in multiple cell systems. The location of the conserved Ser 518 residue at the start of the aB helix within the JAK1 SH2 domain (39) suggests that phosphorylation may disrupt SH2 domain structure sufficiently to uncouple cytokine receptors from JAK1 activation, although this has yet to be tested. We also found that either AMPKa1 knockdown Ten percent of each total cell extract was immunoblotted as indicated; the remainder was incubated with GST/14-3-3z and glutathione-Sepharose beads, and immunoprecipitates were immunoblotted for JAK1. Densitometry of immunoprecipitated JAK1 was normalized to that of the total extract. Data are means ± SEM; n = 3 independent experiments. *P < 0.05 using a one-way ANOVA with Bonferroni post hoc test. (C) Pull-down and immunoblotting as described in (B) in immortalized WT and AMPKa1
−/− /AMPKa2 −/− MEFs treated with A769662 (100 mM) for up to 20 min. Data were analyzed as described in (B). *P < 0.05 and **P < 0.01 using a one-way ANOVA with Bonferroni post hoc test. (D) Pull-down and immunoblotting as described in (B) in HUVECs treated with metformin and salicylate (Met + Sal; 3 and 5 mM, respectively) for the indicated times. Data were analyzed as described in (B). *P < 0.05 using a one-way ANOVA with Dunnett's post hoc test.
or AV-mediated expression of DN AMPKa1 specifically blocked the ability of AMPK activators to suppress STAT3 phosphorylation, thereby ruling out a constitutive suppressive effect of AMPK on JAK-STAT signaling under our conditions. Finally, the existence of several inhibitory mechanisms by which AMPK can suppress JAK-STAT signaling mirrors the multifaceted impact of AMPK on the mTOR signaling pathway, which it inhibits through direct phosphorylation of two components [tuberous sclerosis complex 2 (TSC2) on Ser 1387 (58, 59) and Raptor on Ser and Ser 792 (38) ]. These observations suggest that, like the mTOR pathway, AMPK-mediated regulation of JAK-STAT signaling has also evolved, such that multiple mechanisms and targets are used to limit its activation.
Given the importance of AMPK and JAK-STAT signaling pathways in either inhibiting or stimulating processes such as cell proliferation, longevity, angiogenesis, and inflammation, AMPK-mediated JAK1 phosphorylation could potentially influence these events. Several studies have reported that LKB1, the major kinase responsible for activation loop phosphorylation of AMPKa subunits in response to energy stress, exerts a suppressive effect on STAT3 phosphorylation and function, such that loss of LKB1 increases STAT3 phosphorylation (60) (61) (62) . LKB1 is a tumor suppressor and is frequently inactivated in human cancers (63) , and hyperactivation of STAT3 within tumor cells and the tumor microenvironment has been extensively described (18) . The identification of JAK1 as a target would suggest that AMPK activation might be a useful strategy for limiting STAT3-mediated tumor progression, in addition to its well-described effects on cell growth, proliferation, and autophagy (38, 45, 64) . The ability of AMPK to inhibit STAT phosphorylation after expression of a constitutively active V658F-mutant of JAK1 through a mechanism requiring Ser 515 or Ser 518 would also support clinical studies that evaluate AMPK activators, such as metformin, as potential treatment options for patients with ALL caused by activating JAK1 mutations (49, 65) .
MATERIALS AND METHODS

Reagents
Antibodies against JAK1 were from BD Transduction Laboratories (catalog no. 610232). HRP-conjugated antibodies against GST were from Abcam (catalog no. ab3416). Cytokines and HRP-conjugated 14-3-3z were from R&D Systems. Other antibodies used have been described elsewhere (21, (66) (67) (68) (69) . Peptide arrays were synthesized on glass slides by automatic SPOT synthesis using 9-fluorenylmethyloxycarbonyl chemistry with the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments). AMPK preparations used for in vitro kinase assays were purified from rat liver as previously described (35) . Serotype 5 AVs expressing either GFP (AV.GFP) or a DN mutant AMPKa1 (AV.DN-AMPKa1) were prepared, titered, and used to infect HUVECs as described previously (28, 68, 70) .
Cell culture and transfections SV40-immortalized wild-type and PRKAA1 −/− /PRKAA2 −/− MEFs lacking AMPKa1 and AMPKa2 catalytic subunits, HUVECs, U937 promonocytic cells, and the human fibrosarcoma cell lines 2C4, U4C, and U4C.JAK1 were cultured as previously described (21, 34, 47, 48, 71) . Transient expression of wild-type and mutated JAK1 constructs in U4C cells was performed using PolyFect transfection reagent (Qiagen) in accordance with the manufacturer's instructions. Transfection of HUVECs with siRNAs was performed as previously described (71, 72) .
Expression constructs pGEX4T/14-3-3z was obtained from G. Milligan (University of Glasgow, U.K.). C-terminally Flag-and myc epitope-tagged human JAK1 in pCMV6 was obtained from OriGene (catalog no. RC213878). QuikChange mutagenesis (Agilent Technologies) was used to introduce JAK1 mutations at Ser 515 and Ser 518 to Ala and at Val 658 to Phe. All constructs were sequenced in their entirety to ensure that no additional unanticipated mutations had been introduced.
SDS-PAGE, immunoblotting, and overlays
Cells were washed twice with ice-cold phosphate-buffered saline and lysed by scraping into lysis buffer [50 mM Hepes (pH 7.4), 150 mM sodium chloride, 1% (v/v) Triton X-100, 0.5% (v/v) sodium deoxycholate, 0.1% (w/v) SDS, 10 mM sodium fluoride, 5 mM EDTA, 10 mM sodium phosphate, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), benzamidine (10 mg/ml), soybean trypsin inhibitor (10 mg/ml), and 2% (w/v) cOmplete EDTA-free protease inhibitor cocktail (SigmaAldrich)]. After 30 min on ice, lysates were vortexed and cleared by centrifugation. Equivalent amounts of protein, as determined by bicinchoninic acid protein assay, were fractionated by 8 to 12% SDSpolyacrylamide gel electrophoresis (PAGE) gels, depending on the application, transferred to a nitrocellulose membrane, and analyzed by either immunoblotting or overlay with HRP-14-3-3z, as previously described (68, 71) . Peptide arrays were blocked in 5% (w/v) bovine serum albumin (BSA) in tris-buffered saline containing 0.1% (v/v) Tween 20 (TBST) before overlay with HRP-14-3-3z (1:500 in BSA/TBST) overnight at 4°C, washing, and visualization by enhanced chemiluminescence.
Peptide array AMPK assays Peptide arrays were synthesized as previously described (73) . AMPK phosphorylation of immobilized peptide arrays spotted in duplicate was undertaken with either vehicle or purified rat liver AMPK (0.5 U/ml) (35) 
Pull-down assays and immunoprecipitations
Recombinant GST, GST/14-3-3t, and GST/14-3-3z were produced after induction in Escherichia coli BL21 cells and purified from clarified bacterial extracts using glutathione-Sepharose beads. GST, GST/14-3-3t, or GST/14-3-3z (20 mg) immobilized on glutathione-Sepharose beads was added to protein-equalized clarified cell extracts prepared in pull-down assay buffer [50 mM Hepes (pH 7.4), 120 mM NaCl, 5 mM EDTA, 10% (v/v) glycerol, and 1% (v/v) Triton X-100, supplemented with phosphatase inhibitors, 5 mM sodium fluoride and 1 mM sodium orthovanadate, and protease inhibitors, benzamidine (10 mg/ml), 0.1 mM PMSF, soybean trypsin inhibitor (10 mg/ml), and 2% (w/v) cOmplete EDTA-free protease inhibitor cocktail] and incubated overnight with rotation at 4°C. After washing three times in pull-down assay buffer, samples were eluted in SDS-PAGE sample buffer by incubation at 65°C for 30 min before fractionation on 8% SDS-PAGE gels and immunoblotting with an antibody against JAK1. GST fusion proteins were identified by either probing with HRP-conjugated antibody against GST or Ponceau staining of nitrocellulose blots.
Flag-tagged wild-type and mutated human JAK1 were immunoprecipitated from transfected U4C cells solubilized in immunoprecipitation buffer using Flag M2-Sepharose beads before analysis by SDS-PAGE and immunoblotting as previously described (73) .
Analysis of conditioned medium for chemotactic activity Conditioned medium was obtained from HUVECs preincubated in the presence or absence of 100 mM A769662 for 30 min before incubation with sIL-6Ra (25 ng/ml) and IL-6 (5 ng/ml) for 2 hours. HUVECs were washed before collection of conditioned medium for 1 hour (such that residual sIL-6Ra/IL-6 and A769662 were not in conditioned medium). Conditioned medium from each treatment was then added to the bottom wells of a Boyden chamber, and equal numbers of U937 promonocytic cells were added to the top chamber, which was separated from the bottom by a collagen-coated membrane. After 5 hours, migrated U937 cells were collected from the lower well and counted in urinalysis glasstic slides (Stratagene).
Statistical analysis
Results are expressed as mean ± SEM. Statistically significant differences were determined using a two-tailed t test or one-or two-way ANOVA where appropriate, with P < 0.05 as significant.
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